

Attorney Docket No.: 6809.230-US
Filed: January 30, 2004
Via Facsimile No.: 571-273-8300

Application Serial No.: 10/768,371
Inventors: Igor Gonda et al.

Attorney Docket No.: 6809.230-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

FEB 09 2007

In re Application of: Igor Gonda et al. Confirmation No.: 6533

Serial No.: 10/768,371 Group Art Unit: 3743

Filed: January 30, 2004 Examiner: Mitchell

For: A Method Of Treating Diabetes Mellitus In A Patient

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on November 13, 2006, Reel 018505, Frame 0550).

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

U.S. Patent No. 7,021,309, issued April 4, 2006,
is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

U.S. Patent No. 7,021,309, issued April 4, 2006,
this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal

RECEIVED
CENTRAL FAX CENTER

FEB 09 2007

Attorney Docket No.: 6809.230-US
Filed: January 30, 2004
Via Facsimile No.: 571-273-8300Application Serial No.: 10/768,371
Inventors: Igor Gonda et al.

part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of


U.S. Patent No. 7,021,309, issued April 4, 2006,

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 9, 2007


Marc A. Began, Reg. No. 48,829
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE